rc48-adc
PTCL
Antengene Corporationantibody_drug_conjugatePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 81/ 100
Competitive context
10 Active assets in the PTCL cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Decitabine Ruijin Hospital | Phase 3 | BB |
shr2554 The First Affiliated Hospital with Nanjing Medical University | Phase 3 | B |
Pyrotinib Antengene Corporation | Phase 2 | B |
Zeprumetostat Ruijin Hospital | Phase 2 | B |
yy-20394 Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 2 | B |
View all 13 →
Same molecule, other indications
rc48-adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →